![[Toyota Times] From Strengthening Foundations to Boosting Productivity - Toyota Focuses on Break-Even Volume](https://businessfortnight.com/wp-content/uploads/2025/11/Toyota-Times-From-Strengthening-Foundations-to-Boosting-Productivity-Toyota-218x150.jpg "[Toyota Times] From Strengthening Foundations to Boosting Productivity – Toyota Focuses on Break-Even Volume")
MONTREAL, Nov. 04, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world chief in blood stem cell enlargement and rejuvenation, introduced immediately that an summary associated to ExCellThera’s most superior investigational drug, ECT-001 Cell Therapy, has been accepted for oral presentation on the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, going down December 10-13, 2022. The summary is now obtainable on the ASH web site at www.hematology.org.
The summary and oral presentation embrace findings of a matched-controlled real-world evaluation evaluating outcomes of sufferers handled with ECT-001 Cell Therapy in a Phase 1/2 trial, to twine blood and matched unrelated donor peripheral blood stem cell transplants management cohorts recognized from the CIBMTR® (Center for International Blood and Marrow Transplant Research®) analysis database, together with general survival (OS), progression-free survival (PFS), and graft-versus-host illness and relapse-free survival (GRFS).
ASH 2022 presentation particulars:
| Title: | Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence (Publication no. 665) |
| Date & Time: | Sunday, December 11, 2022, at 5:30PM CT (6:30 PM ET) |
| Location: | Ernest N. Morial Convention Center, 220-222, New Orleans, Louisiana |
| Session: | Cell Collection and Processing I (Session no. 711) |
| Presenter: | Sandra Cohen, MD, FRCP, Maisonneuve Rosemont Hospital, Montreal, Canada |
About ECT-001 Cell Therapy
ECT-001 Cell Therapy combines proprietary molecule UM171, and an optimized tradition system. ECT-001 Cell Therapy has been evaluated in almost 100 grownup and pediatric sufferers with extreme blood problems in a number of scientific trials within the United States and Canada (with further scientific trials in Europe anticipated quickly). ECT-001 Cell Therapy has acquired orphan drug designation and regenerative medication superior remedy (RMAT) designation from the FDA in addition to orphan medicinal product designation, superior remedy medicinal product (ATMP) classification and precedence medicines (PRIME) designation from the EMA.
About ExCellThera
ExCellThera is a world chief in blood stem cell enlargement and rejuvenation. ExCellThera’s lead proprietary molecule, UM171, has develop into the usual for hematopoietic stem cell (HSC) enlargement in cell and gene remedy. UM171’s first-in-class mechanism of motion has been proven to broaden and rejuvenate HSCs, and to counteract exhaustion from tradition and gene modification which symbolize essential limitations in cell and gene therapies. ExCellThera has developed industrial GMP-grade UM171 which may be built-in into the manufacturing course of of varied cell and gene remedy merchandise as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA.
In addition to ECT-001 Cell Therapy, ExCellThera additionally has a pre-clinical pipeline of subsequent technology cell and gene therapies in adjoining fields of use. excellthera.com
